Y Touchefeu1,2, C Bailly3, E Frampas4, T Eugène3, C Rousseau5, M Bourgeois3, C Bossard6, A Faivre-Chauvet3, A Rauscher7, D Masson8, A David4, E Cerato9, T Carlier3, R M Sharkey10, D M Goldenberg10,11, J Barbet12, F Kraeber-Bodere3,13, C Bodet-Milin3. 1. Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, France. yann.touchefeu@chu-nantes.fr. 2. Institut des Maladies de l'Appareil Digestif, University Hospital, Nantes, France. yann.touchefeu@chu-nantes.fr. 3. Université de Nantes, CHU Nantes, CNRS, Inserm, CRCINA, F-44000, Nantes, France. 4. Radiology department, University Hospital, Nantes, France. 5. Université de Nantes, ICO Gauducheau, CNRS, Inserm, CRCINA, F-44000, Nantes, France. 6. Pathology Department, University Hospital, Nantes, France. 7. Pharmacy Unit, ICO Cancer Center, Saint-Herblain, France. 8. Biology Department, University Hospital, Nantes, France. 9. Délégation à la Recherche Clinique et à l'Innovation, University Hospital, Nantes, France. 10. Immunomedics, Inc., Morris Plains, NJ, USA. 11. IBC Pharmaceuticals, Inc., Morris Plains, NJ, USA. 12. GIP Arronax, F-44800, Saint-Herblain, France. 13. Université de Nantes, CHU Nantes, ICO Gauducheau, CNRS, Inserm, CRCINA, F-44000, Nantes, France.
Abstract
INTRODUCTION: This pilot study evaluated the imaging performance of pretargeted immunological positron emission tomography (immuno-PET) using an anti-carcinoembryonic antigen (CEA) recombinant bispecific monoclonal antibody (BsMAb), TF2 and the [68Ga]Ga-labelled HSG peptide, IMP288, in patients with metastatic colorectal carcinoma (CRC). PATIENTS AND METHODS: Patients requiring diagnostic workup of CRC metastases or in case of elevated CEA for surveillance were prospectively studied. They had to present with elevated CEA serum titre or positive CEA tumour staining by immunohistochemistry of a previous biopsy or surgical specimen. All patients underwent endoscopic ultrasound (EUS), chest-abdominal-pelvic computed tomography (CT), abdominal magnetic resonance imaging (MRI) and positron emission tomography using [18F]fluorodeoxyglucose (FDG-PET). For immuno-PET, patients received intravenously 120 nmol of TF2 followed 30 h later by 150 MBq of [68Ga]Ga-labelled IMP288, both I.V. The gold standard was histology and imaging after 6-month follow-up. RESULTS: Eleven patients were included. No adverse effects were reported after BsMAb and peptide injections. In a per-patient analysis, immuno-PET was positive in 9/11 patients. On a per-lesion analysis, 12 of 14 lesions were positive with immuno-PET. Median SUVmax, MTV and TLG were 7.65 [3.98-13.94, SD 3.37], 8.63 cm3 [1.98-46.64; SD 14.83] and 37.90 cm3 [8.07-127.5; SD 43.47] respectively for immuno-PET lesions. Based on a per-lesion analysis, the sensitivity, specificity, positive-predictive value and negative-predictive value were, respectively, 82%, 25%, 82% and 25% for the combination of EUS/CT/MRI; 76%, 67%, 87% and 33% for FDG-PET; and 88%, 100%, 100% and 67% for immuno-PET. Immuno-PET had an impact on management in 2 patients. CONCLUSION: This pilot study showed that pretargeted immuno-PET using anti-CEA/anti-IMP288 BsMAb and a [68Ga]Ga-labelled hapten was safe and feasible, with promising diagnostic performance. TRIAL REGISTRATION: ClinicalTrials.gov NCT02587247 Registered 27 October 2015.
INTRODUCTION: This pilot study evaluated the imaging performance of pretargeted immunological positron emission tomography (immuno-PET) using an anti-carcinoembryonic antigen (CEA) recombinant bispecific monoclonal antibody (BsMAb), TF2 and the [68Ga]Ga-labelled HSG peptide, IMP288, in patients with metastatic colorectal carcinoma (CRC). PATIENTS AND METHODS: Patients requiring diagnostic workup of CRC metastases or in case of elevated CEA for surveillance were prospectively studied. They had to present with elevated CEA serum titre or positive CEAtumour staining by immunohistochemistry of a previous biopsy or surgical specimen. All patients underwent endoscopic ultrasound (EUS), chest-abdominal-pelvic computed tomography (CT), abdominal magnetic resonance imaging (MRI) and positron emission tomography using [18F]fluorodeoxyglucose (FDG-PET). For immuno-PET, patients received intravenously 120 nmol of TF2 followed 30 h later by 150 MBq of [68Ga]Ga-labelled IMP288, both I.V. The gold standard was histology and imaging after 6-month follow-up. RESULTS: Eleven patients were included. No adverse effects were reported after BsMAb and peptide injections. In a per-patient analysis, immuno-PET was positive in 9/11 patients. On a per-lesion analysis, 12 of 14 lesions were positive with immuno-PET. Median SUVmax, MTV and TLG were 7.65 [3.98-13.94, SD 3.37], 8.63 cm3 [1.98-46.64; SD 14.83] and 37.90 cm3 [8.07-127.5; SD 43.47] respectively for immuno-PET lesions. Based on a per-lesion analysis, the sensitivity, specificity, positive-predictive value and negative-predictive value were, respectively, 82%, 25%, 82% and 25% for the combination of EUS/CT/MRI; 76%, 67%, 87% and 33% for FDG-PET; and 88%, 100%, 100% and 67% for immuno-PET. Immuno-PET had an impact on management in 2 patients. CONCLUSION: This pilot study showed that pretargeted immuno-PET using anti-CEA/anti-IMP288BsMAb and a [68Ga]Ga-labelled hapten was safe and feasible, with promising diagnostic performance. TRIAL REGISTRATION: ClinicalTrials.gov NCT02587247 Registered 27 October 2015.
Authors: Edmund A Rossi; David M Goldenberg; Thomas M Cardillo; William J McBride; Robert M Sharkey; Chien-Hsing Chang Journal: Proc Natl Acad Sci U S A Date: 2006-04-24 Impact factor: 11.205
Authors: Pier Paolo Mainenti; Marcello Mancini; Ciro Mainolfi; Luigi Camera; Simone Maurea; Antonietta Manchia; Michela Tanga; Francesco Persico; Pietro Addeo; Dario D'Antonio; Antonio Speranza; Luigi Bucci; Giovanni Persico; Leonardo Pace; Marco Salvatore Journal: Abdom Imaging Date: 2009-06-27
Authors: Jacques Ferlay; Hai-Rim Shin; Freddie Bray; David Forman; Colin Mathers; Donald Maxwell Parkin Journal: Int J Cancer Date: 2010-12-15 Impact factor: 7.396
Authors: Caroline Bodet-Milin; Alain Faivre-Chauvet; Thomas Carlier; Aurore Rauscher; Mickael Bourgeois; Evelyne Cerato; Vincent Rohmer; Olivier Couturier; Delphine Drui; David M Goldenberg; Robert M Sharkey; Jacques Barbet; Francoise Kraeber-Bodere Journal: J Nucl Med Date: 2016-05-26 Impact factor: 10.057
Authors: Dushyant V Sahani; Sanjeeva P Kalva; Alan J Fischman; Rajagopal Kadavigere; Michael Blake; Peter F Hahn; Sanjay Saini Journal: AJR Am J Roentgenol Date: 2005-07 Impact factor: 3.959
Authors: Françoise Kraeber-Bodéré; Caroline Rousseau; Caroline Bodet-Milin; Eric Frampas; Alain Faivre-Chauvet; Aurore Rauscher; Robert M Sharkey; David M Goldenberg; Jean-François Chatal; Jacques Barbet Journal: Front Pharmacol Date: 2015-03-31 Impact factor: 5.810
Authors: Fiona Hegi-Johnson; Stacey Rudd; Rodney J Hicks; Dirk De Ruysscher; Joseph A Trapani; Thomas John; Paul Donnelly; Benjamin Blyth; Gerard Hanna; Sarah Everitt; Peter Roselt; Michael P MacManus Journal: NPJ Precis Oncol Date: 2022-04-07